![Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab](https://oncodaily.com/pub/uploads/2023/09/Polyak-lab-1-1-1280x1280.jpg)
Photo from Polyak Lab/Twitter
Sep 11, 2023, 00:27
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab
Polyak Lab recently shared on X/Twitter:
“Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for TNBC is out in Molecular Cancer Therapeutics today. Congrats to all the coauthors! And of course a lot more to be explored in the future.”
For the article click here.
Source: Polyak Lab/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023